Services

Start Your Project Now!

Please note: Our products and services are not intended to be used directly in diagnostic or therapeutic procedures.

Here's how you can reach us...

Tel:
Email:

Inorganic Nanoparticle Development

Inquiry

CD Formulation specializes in providing full-scale services for delivering nucleic acid treatments through inorganic nanoparticles. Utilizing cutting-edge lab tech and a skilled R&D team, we offer tailored development solutions.

Why Develop Inorganic Nanoparticles?

Inorganic nanoparticles possess distinct chemical and physical traits beneficial for nucleic acid transport systems. They offer high stability and customizable dimensions and can be modified to enhance binding with nucleic acids, thus boosting delivery efficiency. Moreover, inorganic nanomaterials generally exhibit excellent biocompatibility and biodegradability, making them an ideal choice as carriers in delivery systems. Thus, designing nucleic acid drug delivery systems using inorganic nanoparticles provides novel insights and technical means for medical research.

Fig.1 Advantages of FA-siRNA conjugates. Fig.1 Nucleic acids are in inorganic nanoparticles. (CD Formulation)

Explore Our Inorganic Nanoparticle Development Services

Items	Descriptions
Carbon Nanomaterials Development	Carbon nanomaterials include 0D fullerenes and carbon quantum dots, 1D carbon nanotubes/nanohorns and graphene nanoribbons, 2D graphene and graphene oxide, and 3D nanodiamonds.
Silica Nanoparticles Development	Silica nanoparticles (SNP) are extensively studied for drug delivery due to their adjustable porous structure and large surface area, which enable effective gene molecule loading and protection against nuclease degradation. To enhance loading of negatively charged nucleic acids, SNP surfaces can be modified with cationic polymers.
Calcium Nanomaterials Development	In bones and teeth, calcium typically appears as biominerals like phosphate, carbonate, silicate, and fluoride. These calcium-based nanomaterials dissolve readily and merge smoothly into metabolic functions, effectively mitigating concerns regarding the non-biodegradability and lasting toxicity found in alternative substances.
Gold Nanoparticles (Au NP) Development	Au NP offer high tunability in size and shape, meeting the size requirements for loading different drugs such as proteins, nucleic acids, or small molecule drugs.
Magnetic Nanoparticles Development	The design and assembly of magnetic drug delivery systems can involve surface modification of single particles or the hollow and hybrid structures of magnetic nanoparticles. Magnetic nanoparticles can form core-shell structures with coatings of silica, gold, or polymers, enhancing surface modification and drug loading.

Our Solutions for Inorganic Nanoparticle Development

CD Formulation provides clients with tailored solutions for inorganic nanoparticles, encompassing a wide range of analytical services. These services include particle size and morphology characterization, surface chemical analysis, stability testing, and evaluation of nucleic acid drug loading efficiency.

Analysis	Descriptions
Particle Characterization	DLS - Utilized for measuring particle size and size distribution. TEM - Used to observe the morphology and size of inorganic nanoparticles.
Surface Property Analysis	Zeta Potential Analysis - Employed to assess the surface charge of nanoparticles.
Component and Structure Analysis	XRD - Employed in evaluating the crystalline configuration of inorganic nanoparticles. UV-Vis - Applied to assess the samples' optical characteristics.
Drug Encapsulation and Release Analysis	HPLC - Used for quantitative analysis of drug content encapsulated within nanoparticles.

Our Workflow of Inorganic Nanoparticle Development

Fig.2 Development flowchart of FA-siRNA conjugates. Fig.2 Flow chart of inorganic nanoparticle development. (CD Formulation)

Initial Design

Customized schemes for inorganic nanoparticle design are developed based on the properties of nucleic acid drugs, ensuring optimized delivery performance.

Material Testing

Selection of premium inorganic materials is followed by comprehensive testing of their physical and chemical properties to guarantee stability and safety.

Functional Modification

Surface modification techniques are employed to boost the targeting ability and biocompatibility of nanoparticles, enhancing delivery efficiency.

Scale-Up Production

Advanced manufacturing techniques are utilized to achieve efficient and stable mass production, laying the groundwork for subsequent applications.

Quality Control

A rigorous quality monitoring system is in place to ensure products meet international standards, providing reliable support to clients.

Our Technology Platforms

Platforms	Descriptions
Inorganic Nanoparticle Delivery System Platform	Focuses on the development and optimization of inorganic nanoparticles to enhance targeted delivery efficiency of nucleic acid drugs.
HPLC Platform	Provides efficient solutions for separation, purification, and analysis of nanoparticle samples.
UV-Vis Platform	Used for assessing the optical properties of nanoparticles and their stability in various media.
Zeta Potential Analysis Platform	Helps optimize stability and dispersion by measuring the potential of nanoparticles.

Our Advantages of Inorganic Nanoparticle Development

Inorganic nanoparticles boost the delivery and precision of nucleic acid treatments, improving their efficacy.
These particles safeguard nucleic acids against degradation, prolonging their activity.
By tweaking the properties of these nanoparticles, targeted drug release is achieved, enhancing therapeutic success.
Engineered as versatile platforms, they integrate imaging and treatment capabilities for combined diagnostic and therapeutic use.

Publication Data

Technology: Development of various lipid-based nanoparticles using lipid-based nanoplatforms

Journal: Molecular Therapy

IF: 12.4

Published: 2024

Results:

siRNA treatments have the potential to target specific disease genes but face challenges due to cellular barriers, hindering their clinical use. To address this, siRNAs have been modified for better transfection, yet finding efficient delivery mechanisms remains key. Nanoparticles have recently emerged as effective carriers for siRNA, offering reduced toxicity and off-target effects. Patisiran represents an LNP-based siRNA therapy for hereditary transthyretin amyloidosis, illustrating the potential of nanoparticle use. This overview explores the use of lipid, polymer, and inorganic nanoparticles and their subdivisions for siRNA delivery.

Fig.3 Structures of FA-siRNA conjugates. Fig.3 The landscape of nanoparticle-based siRNA delivery. (Moazzam M, et al., 2024)

CD Formulation's offerings can notably boost drug delivery efficiency, enhance therapeutic outcomes, and greatly reduce side effects, all while maintaining formulation stability and control. For further details or to engage in a discussion with our specialists, feel free to reach out to us.

References

Moazzam M, Zhang M, Hussain A, et al. The landscape of nanoparticle-based siRNA delivery and therapeutic development. Mol. Ther. 2024, 32(2): 284-312.

How It Works

STEP 1

Submit a service request describing your specific research or development need.

STEP 2

We'll email you to provide your quote and confirm order details if applicable.

STEP 3

Execute the project with real-time communication, and deliver the final report promptly.

Related Services